Dan's Journey with Laser Focal Therapy Prostate Cancer Treatment

Based in the Houston Medical Center, Dr. Ara Karamanian is a dual board-certified vascular and interventional radiologist specializing in the use of focal laser ablation (FLA) to treat prostate cancer. If you would like to know more, call us at the Prostate Laser Center at (844) MENS-MRI - our team is happy to help you explore and understand your treatment options. You may also call 713-904-4014.
You may also book a free prostate cancer treatment consultation on the Prostate Laser Center website, www.prostatelasercenter.com. There, you will also find information about what to expect should you choose focal laser ablation therapy with another treatment known as TULSA-PRO (Profound Medical, INC.), or transurethral ultrasound ablation procedure.
Dr. Karamanian, is the Director of HALO Diagnostic's Prostate Program and Medical Director of the Prostate Laser Center. Also known to his patients as Dr. K, he has performed hundreds of ablation procedures to treat both prostate cancer and enlarged prostate (BPH). Both FLA and TULSA-PRO can be used to treat both conditions and do not require surgery or incisions; they are outpatient procedures performed in an outpatient setting. Both procedures are performed using real-time MRI guidance and have a demonstrated reduced risk of side effects over other prostate cancer treatments like radical prostatectomy, HIFU, cryoablation, and others.
The Prostate Laser Center is powered by HALO Diagnostics and is a proud partner in providing personalized, precision medicine and therapies to evolve the fight against prostate cancer.
Laser ablation also has a unique advantage over surgery and radiation, which are both whole-gland treatments. Ablation can be done as a focal treatment with added benefits:
Targets only the tumor plus an extra margin of safety tissue
By nature, FLA avoids damage to healthy prostate tissue with closely monitored real-time temperature feedback
Greatly reduces the risk of impaired urinary and sexual function as compared to surgery.
Results from a phase II HALO Diagnostics clinical trial, now in year 12, show promising results. The trial, involving 200 men, demonstrates a less than 1% risk for ED (erectile dysfunction), less than 1% for incontinence, and a 100% prostate cancer-specific survival rate since 2010. Long available outside of the clinical trial, HALO Diagnostics centers have treated more than 800 cases of prostate cancer and benign prostatic hyperplasia (BPH) using LFT.
References: Feller JF, Greenwood BM, Stafford RJ. Imaging and focal therapy of early prostate cancer. Cham: Springer; 2017. Transrectal laser focal therapy of prostate cancer; pp. 325-342.